ArticleBMC cancer2026
A novel "early warning" system for biochemical recurrence in prostate cancer: development and validation of the SII-HALP combined score.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional clinicopathological features often inadequately reflect systemic host-tumor dynamics, compromising the predictive accuracy of biochemical recurrence (BCR) in prostate cancer, particularly with respect to early oncological failure. This study sought to evaluate the SII-HALP combined score-integrating the Systemic Immune-Inflammation Index (SII) and Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score-and assess its time-dependent prognostic value in patients undergoing radical prostatectomy.
methodsClinicopathological data from patients with localized prostate cancer were retrospectively analyzed. Maximally selected rank statistics identified optimal threshold values for SII and HALP. A prognostic nomogram incorporating the combined score was then constructed. Model performance was assessed using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). The incremental predictive value was quantified via integrated discrimination improvement (IDI) and net reclassification improvement (NRI).
resultsMultivariable Cox regression established the SII-HALP combined score as an independent predictor of BCR. The nomogram exhibited an improved predictive performance for 1-year recurrence (AUC 0.866 vs. 0.821 in the base model; P = 0.002). This incremental gain was confirmed by an IDI of 0.067 (P < 0.001) and an NRI of 0.532 (P = 0.040). While the incremental benefit diminished at exploratory 3- and 5-year timepoints as anatomical factors became predominant, DCA indicated a superior net benefit at 1 year across most threshold probabilities, and tentatively at higher thresholds (> 50%) for exploratory long-term projections.
conclusionBased on internal validation, the preliminary SII-HALP combined score may serve as an exploratory, low-cost prognostic tool that contributes to optimizing risk stratification for 1-year biochemical recurrence. Reflecting a possible host-tumor biological interaction, it offers a conceptual pathway for individualized risk triage, pending further robust external validation and extended longitudinal follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.